The satellite symposium at EHA2022 was chaired by Paolo Ghia joined by Federico Pea, Barbara Eichhorst, Shirley D’Sa and Ramón García Sanz. They discussed next-generation BTK inhibitors in the treatment of B-cell malignancies.
Poster presented at EHA2022 describing the results of a subgroup analysis of the MAGNOLIA study: Zanubrutinib in older patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
Report on updates in the treatment of B-cell malignancies presented at ASH 2021.
BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up-to-date with the BeiGene hematology pipeline and clinical trials.
Zanubrutinib (BGB-3111) is a Bruton’s tyrosine kinase inhibitor (BTKi), currently being evaluated in a broad late-stage clinical trials program globally to treat various B-cell malignancies.
